MA43832B1 - Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine - Google Patents

Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine

Info

Publication number
MA43832B1
MA43832B1 MA43832A MA43832A MA43832B1 MA 43832 B1 MA43832 B1 MA 43832B1 MA 43832 A MA43832 A MA 43832A MA 43832 A MA43832 A MA 43832A MA 43832 B1 MA43832 B1 MA 43832B1
Authority
MA
Morocco
Prior art keywords
acid addition
addition salt
methylmethanamine
pyrrol
difluorophenyl
Prior art date
Application number
MA43832A
Other languages
English (en)
Inventor
Aeri Kim
Kwan Hyung Cho
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Priority claimed from PCT/KR2017/002913 external-priority patent/WO2017164575A1/fr
Publication of MA43832B1 publication Critical patent/MA43832B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La présente invention décrit un nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine. Le sel d'addition d'acide ci-dessus décrit présente non seulement une excellente activité inhibitrice de la pompe à protons, une excellente activité inhibitrice des dégâts gastriques et un excellent effet de renforcement des facteurs de défense, mais également une excellente activité d'éradication de h. Pylori et il peut donc être efficacement utilisé pour la prévention et le traitement des lésions gastro-intestinales dues à l'ulcère du tractus gastro-intestinal, à la gastrite, au reflux œsophagien, ou à h. Pylori.
MA43832A 2016-03-25 2017-03-17 Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine MA43832B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160036081 2016-03-25
PCT/KR2017/002913 WO2017164575A1 (fr) 2016-03-25 2017-03-17 Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine

Publications (1)

Publication Number Publication Date
MA43832B1 true MA43832B1 (fr) 2020-08-31

Family

ID=60141235

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43832A MA43832B1 (fr) 2016-03-25 2017-03-17 Nouveau sel d'addition d'acide de 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine

Country Status (28)

Country Link
US (1) US10487053B2 (fr)
EP (1) EP3433232B1 (fr)
JP (1) JP6609065B2 (fr)
KR (2) KR20170113040A (fr)
CN (1) CN108602771B (fr)
AR (1) AR107964A1 (fr)
AU (1) AU2017238917B2 (fr)
CA (1) CA3014753C (fr)
CL (1) CL2018002415A1 (fr)
CO (1) CO2018008834A2 (fr)
DO (2) DOP2018000191A (fr)
ES (1) ES2811478T3 (fr)
HR (1) HRP20201571T1 (fr)
HU (1) HUE053741T2 (fr)
JO (1) JOP20170071B1 (fr)
MA (1) MA43832B1 (fr)
MX (1) MX379775B (fr)
MY (1) MY196355A (fr)
NZ (1) NZ745267A (fr)
PE (1) PE20190169A1 (fr)
PH (1) PH12018501845B1 (fr)
PL (1) PL3433232T3 (fr)
PT (1) PT3433232T (fr)
RS (1) RS60857B1 (fr)
SG (1) SG11201806968RA (fr)
SI (1) SI3433232T1 (fr)
TN (1) TN2018000269A1 (fr)
TW (1) TWI607753B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102081920B1 (ko) 2016-03-25 2020-02-26 주식회사 대웅제약 1-(5-(2,4-다이플루오로페닐)-1-((3-플루오로페닐)술포닐)-4-메톡시-1h-피롤-3-일)-n-메틸메탄아민 염의 신규한 결정형
KR102233455B1 (ko) * 2017-06-21 2021-03-29 주식회사 대웅제약 4-메톡시피롤 유도체의 중간체 제조 방법
KR102126576B1 (ko) 2018-09-19 2020-06-24 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법
PH12022551415A1 (en) * 2019-12-18 2023-11-20 Daewoong Pharmaceutical Co Ltd Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
PT4148050T (pt) * 2020-06-17 2025-01-29 Ildong Pharmaceutical Co Ltd Novo inibidor da secreção ácida e sua utilização
UA130030C2 (uk) * 2020-12-18 2025-10-15 Тевун Фармасутікал Ко., Лтд. Препарат для перорального введення, який містить 1-(5-(2,4-дифлуорфеніл)-1-((3-флуорфеніл)сульфоніл)-4-метокси-1h-пірол-3-іл)-n-метилметанамін
MX2023013984A (es) * 2021-05-26 2023-12-12 Daewoong Pharmaceutical Co Ltd Nueva formulacion para inyeccion que comprende 1-(5-(2,4-difluorofenil)-1-((3-fluorofenil)sulfonil)-4-metoxi-1h- pirrol-3-il)-n-metilmetanamina.
AU2022280595B2 (en) 2021-05-26 2024-11-14 Daewoong Pharmaceutical Co., Ltd. Medicine container comprising liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
EP4356900A4 (fr) * 2021-05-26 2025-08-13 Daewoong Pharmaceutical Co Ltd Nouvelle formulation injectable comprenant de la 1-(5-(2,4-difluorophényl)-1-((3-fluorophényl)sulfonyl)-4-méthoxy-1h-pyrrol-3-yl)-n-méthylméthanamine
CN118541141A (zh) * 2021-12-15 2024-08-23 株式会社大熊制药 非苏拉赞注射组合物的剂量方案
WO2023113458A1 (fr) * 2021-12-15 2023-06-22 Ildong Pharmaceutical Co., Ltd. Nouveau sel de dérivé de 1-sulfonyle pyrrole, son procédé de préparation et composition pharmaceutique le comprenant
WO2023113474A1 (fr) * 2021-12-15 2023-06-22 일동제약(주) Nouveau sel de dérivé 1-sulfonylpyrrole, son procédé de préparation et composition pharmaceutique comprenant celui-ci
WO2023211843A1 (fr) * 2022-04-25 2023-11-02 Daewoong Pharmaceutical Co., Ltd. Bloqueurs d'acide compétitif pour le potassium pour le traitement d'états hypersécrétoires pathologiques
TW202411216A (zh) * 2022-05-23 2024-03-16 南韓商日東製藥股份有限公司 ６－甲氧基吡啶－３－基衍生物之製造方法
KR102975773B1 (ko) * 2022-05-23 2026-06-10 일동제약(주) 6-메톡시피리딘-3-일 유도체의 제조방법
CN117820193A (zh) * 2022-09-29 2024-04-05 安徽皓元药业有限公司 一种非苏拉赞盐酸盐晶型a及其制备方法
KR102938657B1 (ko) * 2023-02-15 2026-03-12 주식회사 대웅제약 4-메톡시 피롤 유도체의 제조 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5173192B2 (ja) * 2004-09-30 2013-03-27 武田薬品工業株式会社 プロトンポンプ阻害薬
KR101115857B1 (ko) * 2005-08-30 2012-04-12 다케다 야쿠힌 고교 가부시키가이샤 산 분비 억제제로서 1-헤테로시클릴술포닐, 2-아미노메틸,5-(헤테로-) 아릴 치환된 1-ｈ-피롤 유도체
US7994205B2 (en) * 2006-03-31 2011-08-09 Takeda Pharmaceutical Company Limited Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors
WO2008036211A1 (fr) * 2006-09-19 2008-03-27 Alevium Pharmaceuticals, Inc. Promédicaments d'inhibiteurs de pompes à protons comprenant le groupe fonctionnel (1h-pyrrol-1-yl)-1h-benzimidazole
US8933105B2 (en) * 2007-02-28 2015-01-13 Takeda Pharmaceutical Company Limited Pyrrole compounds
JP6292736B2 (ja) * 2012-11-19 2018-03-14 ジエンス ハンセン ファーマセウティカル カンパニー リミテッド ピロールスルホンアミド誘導体、その製造法およびその医療用途
JP6343600B2 (ja) * 2013-02-28 2018-06-13 武田薬品工業株式会社 スルホニルクロライド化合物の製造法
KR102084185B1 (ko) * 2013-08-29 2020-03-04 주식회사 대웅제약 테트라히드로사이클로펜타피롤 유도체 및 이의 제조방법
CN106957252B (zh) * 2014-11-19 2019-11-19 连云港恒运药业有限公司 一种质子泵抑制剂中间体及其制备方法
CN104447491B (zh) * 2014-11-19 2017-06-23 连云港恒运医药有限公司 含吡咯环质子泵抑制剂的半富马酸盐及其中间体和医药用途
KR101613245B1 (ko) * 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물

Also Published As

Publication number Publication date
HRP20201571T1 (hr) 2020-12-11
MX2018009220A (es) 2018-09-10
ES2811478T3 (es) 2021-03-12
PH12018501845A1 (en) 2019-05-15
JP6609065B2 (ja) 2019-11-20
SI3433232T1 (sl) 2020-10-30
AR107964A1 (es) 2018-07-04
DOP2018000191A (es) 2018-09-30
US20190031609A1 (en) 2019-01-31
CN108602771B (zh) 2021-07-16
JP2019509320A (ja) 2019-04-04
EP3433232B1 (fr) 2020-07-15
AU2017238917B2 (en) 2019-07-11
HK1254394A1 (zh) 2019-07-19
TN2018000269A1 (en) 2020-01-16
AU2017238917A1 (en) 2018-08-16
DOP2021000001A (es) 2021-03-15
BR112018069540A2 (pt) 2019-01-29
CO2018008834A2 (es) 2018-10-10
CA3014753C (fr) 2023-08-29
PE20190169A1 (es) 2019-02-01
TWI607753B (zh) 2017-12-11
KR20200105771A (ko) 2020-09-09
SG11201806968RA (en) 2018-09-27
EP3433232A1 (fr) 2019-01-30
KR20170113040A (ko) 2017-10-12
MY196355A (en) 2023-03-24
CA3014753A1 (fr) 2017-09-28
JOP20170071B1 (ar) 2021-08-17
PH12018501845B1 (en) 2022-02-18
PL3433232T3 (pl) 2020-12-14
TW201737908A (zh) 2017-11-01
NZ745267A (en) 2020-03-27
HUE053741T2 (hu) 2021-07-28
MX379775B (es) 2025-03-11
EP3433232A4 (fr) 2019-07-31
KR102417830B1 (ko) 2022-07-06
PT3433232T (pt) 2020-07-21
CN108602771A (zh) 2018-09-28
US10487053B2 (en) 2019-11-26
RS60857B1 (sr) 2020-10-30
CL2018002415A1 (es) 2018-12-28

Similar Documents

Publication Publication Date Title
MX379775B (es) Nueva sal de adición ácida de 1-(5-(2,4-difluorfenil)-1-((3-fluorfenil)sulfonil)-4-metoxi-1h-pirrol-3-il)-n-metilmetanamina.
EA201790453A3 (ru) Новая соль присоединения кислоты 1-(5-(2,4-дифторфенил)-1-((3- фторфенил)сульфонил)-4-метокси-1h-пиррол-3-ил)-n-метилметанамина
MA40887B1 (fr) Nouveaux dérivés de 4-méthoxy pyrrole ou leurs sels, et composition pharmaceutique les comprenant
FI3498693T3 (fi) Heterosyklinen yhdiste
SA521422270B1 (ar) Apol1 مثبطات لـ وطرق لاستخدامها
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA202190960A1 (ru) Конденсированные пирролины, которые действуют как ингибиторы убиквитин-специфической протеазы 30 (usp30)
EA201890618A1 (ru) Способы и композиции для лечения состояний, ассоциированных с аномальными воспалительными ответами
MA35639B1 (fr) Compose heterocyclique aromatique dihydroxy
WO2018182051A8 (fr) Inhibiteurs d'ip6k
CA3015494C (fr) Nouvelles compositions et methodes therapeutiques
EP3417853A4 (fr) Composition pharmaceutique pour le traitement d'un cancer, contenant un composé polyphénol utilisé comme principe actif
EA202190621A1 (ru) Фармацевтическая композиция, содержащая антитромбоцитарное средство и ингибитор секреции желудочной кислоты
Santin et al. Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions
ECSP17072984A (es) Procesos farmacéuticos novedosos
CA3156340A1 (fr) Compose de n-(1h-imidazol-2-yl)benzamide et composition pharmaceutique le comprenant en tant que principe actif
EA201691962A1 (ru) Амидозамещенные азольные соединения в качестве ингибиторов tnks1 и/или tnks2
EA201991490A1 (ru) Ароматические амиды карбоновых кислот в качестве антагонистов рецепторов брадикинина в1
EP3834834A4 (fr) Médicament utilisé pour traiter la nécrose tissulaire ou pour améliorer la fonction cardiaque
PH12022551415A1 (en) Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1h-pyrrol-3-yl)-n-methylmethanamine
MA49396A (fr) Traitement de la migraine avec acétyl-leucine
FR3047665B1 (fr) Celastrol et ses derives dans le traitement des tumeurs et pathologies pre-cancereuses cutanees
EA202191477A1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
TH1801004904A (th) เกลือเพิ่มกรดแบบใหม่ของ 1-(5-(2,4-ไดฟลูออโรฟีนิล)-1-((3-ฟลูออโรฟีนิล)ซัลโฟนิล)-4-มีท็อกซี-1h-ไพร์โรล-3-อิล)-n-เมทิลมีเทนอะมีน
EP3831397A4 (fr) Composition pharmaceutique comprenant comme principe actif de la proanthocyanidine pour la prévention ou le traitement du carcinome épidermoïde